Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Completed 11Recruiting 4Active not recruiting 3Terminated 1

Sponsor Class

OTHER 7INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Burkitt Lymphoma 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Acetaminophen × Clear all
NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
340 enrolled
Lymphoid

Burkitt Lymphoma

NCT06788912 2026-06-01

MK-3475-01E

Merck Sharp & Dohme LLC

Phase 2 Recruiting
60 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT06824467 2026-05-29

TroFuse-022

Merck Sharp & Dohme LLC

Phase 3 Recruiting
770 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡